



TO

All Providers, HMOs and Other Managed Care Programs

REGARDING

Coverage of Second COVID-19 Vaccine Booster Dose and Access to Therapeutics

Coverage of Second COVID-19 Vaccine Booster Dose and Access to Therapeutics

ForwardHealth Covers Second COVID-19 Vaccine Booster Dose

Effective for dates of service on and after March 29, 2022, ForwardHealth reimburses providers for the administration of a second booster dose of the Pfizer (ages 12 and up) and Moderna (ages 18 and up) COVID-19 vaccines following a completed series and first booster dose.

The Wisconsin Department of Health Services (DHS), the U.S. Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention recommend that adults ages 50 and older receive a second COVID-19 booster dose if it has been at least four months since their first booster dose. A second booster dose is especially recommended for adults in long-term care settings such as residential care, assisted living, nursing homes, and continuing care retirement communities.

The reimbursement rate for the administration of a second booster dose of the COVID-19 vaccine is \$38.16, which aligns with the Medicare reimbursement rate geographically adjusted for Wisconsin.

Providers should include the following Current Procedural Terminology procedure codes on claims for vaccine administration of the second booster dose.

PFIZER PROCEDURE CODE	DESCRIPTION
0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose

PFIZER PROCEDURE CODE	DESCRIPTION
0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose

MODERNA PROCEDURE CODE	DESCRIPTION
0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose

Note: The 50 mcg/0.25 mL dosage of the Moderna COVID-19 vaccine booster (procedure code 0064A) is intended for the **first** booster dose, but it may be used for the second booster dose until the 50 mcg/0.5 mL dosage (procedure code 0094A) is available.

The following ForwardHealth Updates contain guidance about the COVID-19 vaccine policy:

- [2021-01](#), “COVID-19 Vaccine Billing and Reimbursement”
- [2021-09](#), “COVID-19 Vaccine Policy and Coverage Clarifications”
- [2021-18](#), “Hospital Billing for COVID-19 Vaccine Administration”

COVID-19 Therapeutics Are Available for Ordering

Pharmacy partners may order COVID-19 therapeutics from DHS. To learn more about accessing a supply of therapeutics (such as oral antiviral pills or monoclonal antibodies), email DHS Operations at dhsoperations@dhs.wisconsin.gov. ForwardHealth will cover COVID-19 therapeutics without cost sharing for a year and a quarter [after the end of the federal public health emergency](#).

The oral antiviral pills Paxlovid and molnupiravir are authorized by the FDA for patients with mild to moderate COVID-19 disease. Oral antiviral drugs can help prevent severe illness, hospitalization, and death by stopping the virus that causes COVID-19 from replicating in the body. They must be administered as soon as possible and within the first five days of symptom onset in order to be effective.

Monoclonal antibody treatments are available through FDA Emergency Use Authorization (EUA) for the prevention and outpatient treatment of COVID-19. Monoclonal antibodies mimic the body’s immune

response to help boost the body's defense against COVID-19. Wisconsin currently receives allocations of two kinds of monoclonal antibodies:

- Bebtelovimab to treat patients diagnosed with mild to moderate COVID-19
- Evusheld for prevention of COVID-19 in people unlikely to produce an immune response to COVID-19 vaccination

Additional resources can be found through the [Centers for Medicare & Medicaid Services](#) website, including information about currently authorized vaccines and monoclonal antibodies, EUAs, and fact sheets for health care providers.